Patients with rheumatoid arthritis achieving clinical deep remission (CliDR) maintain long-term remission better than those meeting less stringent criteria.
2
In a study of 145 patients, 63% in the CliDR group maintained sustained remission at 5 years, compared to 38% in the non-CliDR group.
3
Relapse rates were significantly lower in the CliDR group, with only 12 relapses compared to 70 in the non-CliDR group.
4
Tapering treatment increased relapse risk 8.5-fold in non-CliDR patients, while the risk was significantly lower in the CliDR group.
5
The study highlights that deeper remission may offer better prognostic information for treatment tapering decisions in rheumatoid arthritis.
The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.
